In Vivo Imaging Systems Search Results


ivscope 8200 small animal  (Clinx Science)
95
Clinx Science ivscope 8200 small animal
Ivscope 8200 Small Animal, supplied by Clinx Science, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ivscope 8200 small animal/product/Clinx Science
Average 95 stars, based on 1 article reviews
ivscope 8200 small animal - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
fobi in vivo imaging system  (Cellgentek)
95
Cellgentek fobi in vivo imaging system
Fobi In Vivo Imaging System, supplied by Cellgentek, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fobi in vivo imaging system/product/Cellgentek
Average 95 stars, based on 1 article reviews
fobi in vivo imaging system - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
ivis lumina iii xrms  (Revvity)
91
Revvity ivis lumina iii xrms
MITF expression in MDSCs regulates tumor progression in vivo. (A) The experimental design for the mouse in vivo model. (B–M) MDSCs from the splenocytes of 4T1-bearing mice were isolated by magnetic-activated cell sorting (MACS). Splenic MDSCs were cultured in complete medium containing 10 ng/mL GM-CSF and TCCM or GM-CSF only and then treated with ML-329 (2 µM) or IBMX (10 µM) for 48 hours. (B, H) To evaluate the effect of MITF modulation on tumor development, Balb/c mice were subcutaneously injected with 4T1-luc2 cells alone or coinjected at a 1:1 or 1:2 ratio with DMSO-treated, ML-329-treated or IBMX-treated MDSCs into the mammary fat pad. The tumor volume of the 4T1-bearing mice from five mice/group (B) and six mice/group (H) was measured by a vernier caliper and recorded for the indicated time points. (C, I) Tumor weight was measured on day 21. (D, J) The 4T1-bearing mice were intraperitoneally injected with 3 mg D-luciferin per mouse. After the injection, the mice were anesthetized with isoflurane, and representative bioluminescence images were analyzed using <t>IVIS.</t> (E, K) The tumor-associated immune cells from the 4T1-bearing mice were stained with CD11b, Gr1, and CD45 antibodies and analyzed by flow cytometry. (F, G, L, M) To evaluate the effect of MDSCs on the activity of T cells, harvested tumor-associated cells were stained with IFN-γ, CD4, CD8, and CD45 antibodies. IFN-γ-positive tumor-infiltrating CD4 (F, L) or CD8 (G, M) cells were evaluated by flow cytometry. *P<0.05, **P<0.01, ***P<0.001. GM-CSF, granulocyte–macrophage colony-stimulating factor; IFN-γ, interferon gamma; MDSC, myeloid-derived suppressor cell; MITF, microphthalmia-associated transcription factor; TCCM, tumor cell-conditioned medium.
Ivis Lumina Iii Xrms, supplied by Revvity, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ivis lumina iii xrms/product/Revvity
Average 91 stars, based on 1 article reviews
ivis lumina iii xrms - by Bioz Stars, 2026-05
91/100 stars
  Buy from Supplier
ivis lumina iii imaging system  (Revvity)
95
Revvity ivis lumina iii imaging system
MITF expression in MDSCs regulates tumor progression in vivo. (A) The experimental design for the mouse in vivo model. (B–M) MDSCs from the splenocytes of 4T1-bearing mice were isolated by magnetic-activated cell sorting (MACS). Splenic MDSCs were cultured in complete medium containing 10 ng/mL GM-CSF and TCCM or GM-CSF only and then treated with ML-329 (2 µM) or IBMX (10 µM) for 48 hours. (B, H) To evaluate the effect of MITF modulation on tumor development, Balb/c mice were subcutaneously injected with 4T1-luc2 cells alone or coinjected at a 1:1 or 1:2 ratio with DMSO-treated, ML-329-treated or IBMX-treated MDSCs into the mammary fat pad. The tumor volume of the 4T1-bearing mice from five mice/group (B) and six mice/group (H) was measured by a vernier caliper and recorded for the indicated time points. (C, I) Tumor weight was measured on day 21. (D, J) The 4T1-bearing mice were intraperitoneally injected with 3 mg D-luciferin per mouse. After the injection, the mice were anesthetized with isoflurane, and representative bioluminescence images were analyzed using <t>IVIS.</t> (E, K) The tumor-associated immune cells from the 4T1-bearing mice were stained with CD11b, Gr1, and CD45 antibodies and analyzed by flow cytometry. (F, G, L, M) To evaluate the effect of MDSCs on the activity of T cells, harvested tumor-associated cells were stained with IFN-γ, CD4, CD8, and CD45 antibodies. IFN-γ-positive tumor-infiltrating CD4 (F, L) or CD8 (G, M) cells were evaluated by flow cytometry. *P<0.05, **P<0.01, ***P<0.001. GM-CSF, granulocyte–macrophage colony-stimulating factor; IFN-γ, interferon gamma; MDSC, myeloid-derived suppressor cell; MITF, microphthalmia-associated transcription factor; TCCM, tumor cell-conditioned medium.
Ivis Lumina Iii Imaging System, supplied by Revvity, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ivis lumina iii imaging system/product/Revvity
Average 95 stars, based on 1 article reviews
ivis lumina iii imaging system - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
fmt 2000  (Revvity)
90
Revvity fmt 2000
MITF expression in MDSCs regulates tumor progression in vivo. (A) The experimental design for the mouse in vivo model. (B–M) MDSCs from the splenocytes of 4T1-bearing mice were isolated by magnetic-activated cell sorting (MACS). Splenic MDSCs were cultured in complete medium containing 10 ng/mL GM-CSF and TCCM or GM-CSF only and then treated with ML-329 (2 µM) or IBMX (10 µM) for 48 hours. (B, H) To evaluate the effect of MITF modulation on tumor development, Balb/c mice were subcutaneously injected with 4T1-luc2 cells alone or coinjected at a 1:1 or 1:2 ratio with DMSO-treated, ML-329-treated or IBMX-treated MDSCs into the mammary fat pad. The tumor volume of the 4T1-bearing mice from five mice/group (B) and six mice/group (H) was measured by a vernier caliper and recorded for the indicated time points. (C, I) Tumor weight was measured on day 21. (D, J) The 4T1-bearing mice were intraperitoneally injected with 3 mg D-luciferin per mouse. After the injection, the mice were anesthetized with isoflurane, and representative bioluminescence images were analyzed using <t>IVIS.</t> (E, K) The tumor-associated immune cells from the 4T1-bearing mice were stained with CD11b, Gr1, and CD45 antibodies and analyzed by flow cytometry. (F, G, L, M) To evaluate the effect of MDSCs on the activity of T cells, harvested tumor-associated cells were stained with IFN-γ, CD4, CD8, and CD45 antibodies. IFN-γ-positive tumor-infiltrating CD4 (F, L) or CD8 (G, M) cells were evaluated by flow cytometry. *P<0.05, **P<0.01, ***P<0.001. GM-CSF, granulocyte–macrophage colony-stimulating factor; IFN-γ, interferon gamma; MDSC, myeloid-derived suppressor cell; MITF, microphthalmia-associated transcription factor; TCCM, tumor cell-conditioned medium.
Fmt 2000, supplied by Revvity, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fmt 2000/product/Revvity
Average 90 stars, based on 1 article reviews
fmt 2000 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
bioluminescent imaging system  (Revvity)
94
Revvity bioluminescent imaging system
MITF expression in MDSCs regulates tumor progression in vivo. (A) The experimental design for the mouse in vivo model. (B–M) MDSCs from the splenocytes of 4T1-bearing mice were isolated by magnetic-activated cell sorting (MACS). Splenic MDSCs were cultured in complete medium containing 10 ng/mL GM-CSF and TCCM or GM-CSF only and then treated with ML-329 (2 µM) or IBMX (10 µM) for 48 hours. (B, H) To evaluate the effect of MITF modulation on tumor development, Balb/c mice were subcutaneously injected with 4T1-luc2 cells alone or coinjected at a 1:1 or 1:2 ratio with DMSO-treated, ML-329-treated or IBMX-treated MDSCs into the mammary fat pad. The tumor volume of the 4T1-bearing mice from five mice/group (B) and six mice/group (H) was measured by a vernier caliper and recorded for the indicated time points. (C, I) Tumor weight was measured on day 21. (D, J) The 4T1-bearing mice were intraperitoneally injected with 3 mg D-luciferin per mouse. After the injection, the mice were anesthetized with isoflurane, and representative bioluminescence images were analyzed using <t>IVIS.</t> (E, K) The tumor-associated immune cells from the 4T1-bearing mice were stained with CD11b, Gr1, and CD45 antibodies and analyzed by flow cytometry. (F, G, L, M) To evaluate the effect of MDSCs on the activity of T cells, harvested tumor-associated cells were stained with IFN-γ, CD4, CD8, and CD45 antibodies. IFN-γ-positive tumor-infiltrating CD4 (F, L) or CD8 (G, M) cells were evaluated by flow cytometry. *P<0.05, **P<0.01, ***P<0.001. GM-CSF, granulocyte–macrophage colony-stimulating factor; IFN-γ, interferon gamma; MDSC, myeloid-derived suppressor cell; MITF, microphthalmia-associated transcription factor; TCCM, tumor cell-conditioned medium.
Bioluminescent Imaging System, supplied by Revvity, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bioluminescent imaging system/product/Revvity
Average 94 stars, based on 1 article reviews
bioluminescent imaging system - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
2d reflectance imaging  (Revvity)
91
Revvity 2d reflectance imaging
MITF expression in MDSCs regulates tumor progression in vivo. (A) The experimental design for the mouse in vivo model. (B–M) MDSCs from the splenocytes of 4T1-bearing mice were isolated by magnetic-activated cell sorting (MACS). Splenic MDSCs were cultured in complete medium containing 10 ng/mL GM-CSF and TCCM or GM-CSF only and then treated with ML-329 (2 µM) or IBMX (10 µM) for 48 hours. (B, H) To evaluate the effect of MITF modulation on tumor development, Balb/c mice were subcutaneously injected with 4T1-luc2 cells alone or coinjected at a 1:1 or 1:2 ratio with DMSO-treated, ML-329-treated or IBMX-treated MDSCs into the mammary fat pad. The tumor volume of the 4T1-bearing mice from five mice/group (B) and six mice/group (H) was measured by a vernier caliper and recorded for the indicated time points. (C, I) Tumor weight was measured on day 21. (D, J) The 4T1-bearing mice were intraperitoneally injected with 3 mg D-luciferin per mouse. After the injection, the mice were anesthetized with isoflurane, and representative bioluminescence images were analyzed using <t>IVIS.</t> (E, K) The tumor-associated immune cells from the 4T1-bearing mice were stained with CD11b, Gr1, and CD45 antibodies and analyzed by flow cytometry. (F, G, L, M) To evaluate the effect of MDSCs on the activity of T cells, harvested tumor-associated cells were stained with IFN-γ, CD4, CD8, and CD45 antibodies. IFN-γ-positive tumor-infiltrating CD4 (F, L) or CD8 (G, M) cells were evaluated by flow cytometry. *P<0.05, **P<0.01, ***P<0.001. GM-CSF, granulocyte–macrophage colony-stimulating factor; IFN-γ, interferon gamma; MDSC, myeloid-derived suppressor cell; MITF, microphthalmia-associated transcription factor; TCCM, tumor cell-conditioned medium.
2d Reflectance Imaging, supplied by Revvity, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/2d reflectance imaging/product/Revvity
Average 91 stars, based on 1 article reviews
2d reflectance imaging - by Bioz Stars, 2026-05
91/100 stars
  Buy from Supplier
ivis spectrumct  (Revvity)
92
Revvity ivis spectrumct
MITF expression in MDSCs regulates tumor progression in vivo. (A) The experimental design for the mouse in vivo model. (B–M) MDSCs from the splenocytes of 4T1-bearing mice were isolated by magnetic-activated cell sorting (MACS). Splenic MDSCs were cultured in complete medium containing 10 ng/mL GM-CSF and TCCM or GM-CSF only and then treated with ML-329 (2 µM) or IBMX (10 µM) for 48 hours. (B, H) To evaluate the effect of MITF modulation on tumor development, Balb/c mice were subcutaneously injected with 4T1-luc2 cells alone or coinjected at a 1:1 or 1:2 ratio with DMSO-treated, ML-329-treated or IBMX-treated MDSCs into the mammary fat pad. The tumor volume of the 4T1-bearing mice from five mice/group (B) and six mice/group (H) was measured by a vernier caliper and recorded for the indicated time points. (C, I) Tumor weight was measured on day 21. (D, J) The 4T1-bearing mice were intraperitoneally injected with 3 mg D-luciferin per mouse. After the injection, the mice were anesthetized with isoflurane, and representative bioluminescence images were analyzed using <t>IVIS.</t> (E, K) The tumor-associated immune cells from the 4T1-bearing mice were stained with CD11b, Gr1, and CD45 antibodies and analyzed by flow cytometry. (F, G, L, M) To evaluate the effect of MDSCs on the activity of T cells, harvested tumor-associated cells were stained with IFN-γ, CD4, CD8, and CD45 antibodies. IFN-γ-positive tumor-infiltrating CD4 (F, L) or CD8 (G, M) cells were evaluated by flow cytometry. *P<0.05, **P<0.01, ***P<0.001. GM-CSF, granulocyte–macrophage colony-stimulating factor; IFN-γ, interferon gamma; MDSC, myeloid-derived suppressor cell; MITF, microphthalmia-associated transcription factor; TCCM, tumor cell-conditioned medium.
Ivis Spectrumct, supplied by Revvity, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ivis spectrumct/product/Revvity
Average 92 stars, based on 1 article reviews
ivis spectrumct - by Bioz Stars, 2026-05
92/100 stars
  Buy from Supplier
multimodal ivis lumina xr imaging system  (Revvity)
93
Revvity multimodal ivis lumina xr imaging system
MITF expression in MDSCs regulates tumor progression in vivo. (A) The experimental design for the mouse in vivo model. (B–M) MDSCs from the splenocytes of 4T1-bearing mice were isolated by magnetic-activated cell sorting (MACS). Splenic MDSCs were cultured in complete medium containing 10 ng/mL GM-CSF and TCCM or GM-CSF only and then treated with ML-329 (2 µM) or IBMX (10 µM) for 48 hours. (B, H) To evaluate the effect of MITF modulation on tumor development, Balb/c mice were subcutaneously injected with 4T1-luc2 cells alone or coinjected at a 1:1 or 1:2 ratio with DMSO-treated, ML-329-treated or IBMX-treated MDSCs into the mammary fat pad. The tumor volume of the 4T1-bearing mice from five mice/group (B) and six mice/group (H) was measured by a vernier caliper and recorded for the indicated time points. (C, I) Tumor weight was measured on day 21. (D, J) The 4T1-bearing mice were intraperitoneally injected with 3 mg D-luciferin per mouse. After the injection, the mice were anesthetized with isoflurane, and representative bioluminescence images were analyzed using <t>IVIS.</t> (E, K) The tumor-associated immune cells from the 4T1-bearing mice were stained with CD11b, Gr1, and CD45 antibodies and analyzed by flow cytometry. (F, G, L, M) To evaluate the effect of MDSCs on the activity of T cells, harvested tumor-associated cells were stained with IFN-γ, CD4, CD8, and CD45 antibodies. IFN-γ-positive tumor-infiltrating CD4 (F, L) or CD8 (G, M) cells were evaluated by flow cytometry. *P<0.05, **P<0.01, ***P<0.001. GM-CSF, granulocyte–macrophage colony-stimulating factor; IFN-γ, interferon gamma; MDSC, myeloid-derived suppressor cell; MITF, microphthalmia-associated transcription factor; TCCM, tumor cell-conditioned medium.
Multimodal Ivis Lumina Xr Imaging System, supplied by Revvity, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/multimodal ivis lumina xr imaging system/product/Revvity
Average 93 stars, based on 1 article reviews
multimodal ivis lumina xr imaging system - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
ivis spectrum oi system  (Revvity)
91
Revvity ivis spectrum oi system
MITF expression in MDSCs regulates tumor progression in vivo. (A) The experimental design for the mouse in vivo model. (B–M) MDSCs from the splenocytes of 4T1-bearing mice were isolated by magnetic-activated cell sorting (MACS). Splenic MDSCs were cultured in complete medium containing 10 ng/mL GM-CSF and TCCM or GM-CSF only and then treated with ML-329 (2 µM) or IBMX (10 µM) for 48 hours. (B, H) To evaluate the effect of MITF modulation on tumor development, Balb/c mice were subcutaneously injected with 4T1-luc2 cells alone or coinjected at a 1:1 or 1:2 ratio with DMSO-treated, ML-329-treated or IBMX-treated MDSCs into the mammary fat pad. The tumor volume of the 4T1-bearing mice from five mice/group (B) and six mice/group (H) was measured by a vernier caliper and recorded for the indicated time points. (C, I) Tumor weight was measured on day 21. (D, J) The 4T1-bearing mice were intraperitoneally injected with 3 mg D-luciferin per mouse. After the injection, the mice were anesthetized with isoflurane, and representative bioluminescence images were analyzed using <t>IVIS.</t> (E, K) The tumor-associated immune cells from the 4T1-bearing mice were stained with CD11b, Gr1, and CD45 antibodies and analyzed by flow cytometry. (F, G, L, M) To evaluate the effect of MDSCs on the activity of T cells, harvested tumor-associated cells were stained with IFN-γ, CD4, CD8, and CD45 antibodies. IFN-γ-positive tumor-infiltrating CD4 (F, L) or CD8 (G, M) cells were evaluated by flow cytometry. *P<0.05, **P<0.01, ***P<0.001. GM-CSF, granulocyte–macrophage colony-stimulating factor; IFN-γ, interferon gamma; MDSC, myeloid-derived suppressor cell; MITF, microphthalmia-associated transcription factor; TCCM, tumor cell-conditioned medium.
Ivis Spectrum Oi System, supplied by Revvity, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ivis spectrum oi system/product/Revvity
Average 91 stars, based on 1 article reviews
ivis spectrum oi system - by Bioz Stars, 2026-05
91/100 stars
  Buy from Supplier
fluorescence molecular tomography fmt system  (Revvity)
90
Revvity fluorescence molecular tomography fmt system
MITF expression in MDSCs regulates tumor progression in vivo. (A) The experimental design for the mouse in vivo model. (B–M) MDSCs from the splenocytes of 4T1-bearing mice were isolated by magnetic-activated cell sorting (MACS). Splenic MDSCs were cultured in complete medium containing 10 ng/mL GM-CSF and TCCM or GM-CSF only and then treated with ML-329 (2 µM) or IBMX (10 µM) for 48 hours. (B, H) To evaluate the effect of MITF modulation on tumor development, Balb/c mice were subcutaneously injected with 4T1-luc2 cells alone or coinjected at a 1:1 or 1:2 ratio with DMSO-treated, ML-329-treated or IBMX-treated MDSCs into the mammary fat pad. The tumor volume of the 4T1-bearing mice from five mice/group (B) and six mice/group (H) was measured by a vernier caliper and recorded for the indicated time points. (C, I) Tumor weight was measured on day 21. (D, J) The 4T1-bearing mice were intraperitoneally injected with 3 mg D-luciferin per mouse. After the injection, the mice were anesthetized with isoflurane, and representative bioluminescence images were analyzed using <t>IVIS.</t> (E, K) The tumor-associated immune cells from the 4T1-bearing mice were stained with CD11b, Gr1, and CD45 antibodies and analyzed by flow cytometry. (F, G, L, M) To evaluate the effect of MDSCs on the activity of T cells, harvested tumor-associated cells were stained with IFN-γ, CD4, CD8, and CD45 antibodies. IFN-γ-positive tumor-infiltrating CD4 (F, L) or CD8 (G, M) cells were evaluated by flow cytometry. *P<0.05, **P<0.01, ***P<0.001. GM-CSF, granulocyte–macrophage colony-stimulating factor; IFN-γ, interferon gamma; MDSC, myeloid-derived suppressor cell; MITF, microphthalmia-associated transcription factor; TCCM, tumor cell-conditioned medium.
Fluorescence Molecular Tomography Fmt System, supplied by Revvity, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fluorescence molecular tomography fmt system/product/Revvity
Average 90 stars, based on 1 article reviews
fluorescence molecular tomography fmt system - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
ivscope 8500  (Clinx Science)
94
Clinx Science ivscope 8500
MITF expression in MDSCs regulates tumor progression in vivo. (A) The experimental design for the mouse in vivo model. (B–M) MDSCs from the splenocytes of 4T1-bearing mice were isolated by magnetic-activated cell sorting (MACS). Splenic MDSCs were cultured in complete medium containing 10 ng/mL GM-CSF and TCCM or GM-CSF only and then treated with ML-329 (2 µM) or IBMX (10 µM) for 48 hours. (B, H) To evaluate the effect of MITF modulation on tumor development, Balb/c mice were subcutaneously injected with 4T1-luc2 cells alone or coinjected at a 1:1 or 1:2 ratio with DMSO-treated, ML-329-treated or IBMX-treated MDSCs into the mammary fat pad. The tumor volume of the 4T1-bearing mice from five mice/group (B) and six mice/group (H) was measured by a vernier caliper and recorded for the indicated time points. (C, I) Tumor weight was measured on day 21. (D, J) The 4T1-bearing mice were intraperitoneally injected with 3 mg D-luciferin per mouse. After the injection, the mice were anesthetized with isoflurane, and representative bioluminescence images were analyzed using <t>IVIS.</t> (E, K) The tumor-associated immune cells from the 4T1-bearing mice were stained with CD11b, Gr1, and CD45 antibodies and analyzed by flow cytometry. (F, G, L, M) To evaluate the effect of MDSCs on the activity of T cells, harvested tumor-associated cells were stained with IFN-γ, CD4, CD8, and CD45 antibodies. IFN-γ-positive tumor-infiltrating CD4 (F, L) or CD8 (G, M) cells were evaluated by flow cytometry. *P<0.05, **P<0.01, ***P<0.001. GM-CSF, granulocyte–macrophage colony-stimulating factor; IFN-γ, interferon gamma; MDSC, myeloid-derived suppressor cell; MITF, microphthalmia-associated transcription factor; TCCM, tumor cell-conditioned medium.
Ivscope 8500, supplied by Clinx Science, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ivscope 8500/product/Clinx Science
Average 94 stars, based on 1 article reviews
ivscope 8500 - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

Image Search Results


MITF expression in MDSCs regulates tumor progression in vivo. (A) The experimental design for the mouse in vivo model. (B–M) MDSCs from the splenocytes of 4T1-bearing mice were isolated by magnetic-activated cell sorting (MACS). Splenic MDSCs were cultured in complete medium containing 10 ng/mL GM-CSF and TCCM or GM-CSF only and then treated with ML-329 (2 µM) or IBMX (10 µM) for 48 hours. (B, H) To evaluate the effect of MITF modulation on tumor development, Balb/c mice were subcutaneously injected with 4T1-luc2 cells alone or coinjected at a 1:1 or 1:2 ratio with DMSO-treated, ML-329-treated or IBMX-treated MDSCs into the mammary fat pad. The tumor volume of the 4T1-bearing mice from five mice/group (B) and six mice/group (H) was measured by a vernier caliper and recorded for the indicated time points. (C, I) Tumor weight was measured on day 21. (D, J) The 4T1-bearing mice were intraperitoneally injected with 3 mg D-luciferin per mouse. After the injection, the mice were anesthetized with isoflurane, and representative bioluminescence images were analyzed using IVIS. (E, K) The tumor-associated immune cells from the 4T1-bearing mice were stained with CD11b, Gr1, and CD45 antibodies and analyzed by flow cytometry. (F, G, L, M) To evaluate the effect of MDSCs on the activity of T cells, harvested tumor-associated cells were stained with IFN-γ, CD4, CD8, and CD45 antibodies. IFN-γ-positive tumor-infiltrating CD4 (F, L) or CD8 (G, M) cells were evaluated by flow cytometry. *P<0.05, **P<0.01, ***P<0.001. GM-CSF, granulocyte–macrophage colony-stimulating factor; IFN-γ, interferon gamma; MDSC, myeloid-derived suppressor cell; MITF, microphthalmia-associated transcription factor; TCCM, tumor cell-conditioned medium.

Journal: Journal for Immunotherapy of Cancer

Article Title: Novel role of microphthalmia-associated transcription factor in modulating the differentiation and immunosuppressive functions of myeloid-derived suppressor cells

doi: 10.1136/jitc-2022-005699

Figure Lengend Snippet: MITF expression in MDSCs regulates tumor progression in vivo. (A) The experimental design for the mouse in vivo model. (B–M) MDSCs from the splenocytes of 4T1-bearing mice were isolated by magnetic-activated cell sorting (MACS). Splenic MDSCs were cultured in complete medium containing 10 ng/mL GM-CSF and TCCM or GM-CSF only and then treated with ML-329 (2 µM) or IBMX (10 µM) for 48 hours. (B, H) To evaluate the effect of MITF modulation on tumor development, Balb/c mice were subcutaneously injected with 4T1-luc2 cells alone or coinjected at a 1:1 or 1:2 ratio with DMSO-treated, ML-329-treated or IBMX-treated MDSCs into the mammary fat pad. The tumor volume of the 4T1-bearing mice from five mice/group (B) and six mice/group (H) was measured by a vernier caliper and recorded for the indicated time points. (C, I) Tumor weight was measured on day 21. (D, J) The 4T1-bearing mice were intraperitoneally injected with 3 mg D-luciferin per mouse. After the injection, the mice were anesthetized with isoflurane, and representative bioluminescence images were analyzed using IVIS. (E, K) The tumor-associated immune cells from the 4T1-bearing mice were stained with CD11b, Gr1, and CD45 antibodies and analyzed by flow cytometry. (F, G, L, M) To evaluate the effect of MDSCs on the activity of T cells, harvested tumor-associated cells were stained with IFN-γ, CD4, CD8, and CD45 antibodies. IFN-γ-positive tumor-infiltrating CD4 (F, L) or CD8 (G, M) cells were evaluated by flow cytometry. *P<0.05, **P<0.01, ***P<0.001. GM-CSF, granulocyte–macrophage colony-stimulating factor; IFN-γ, interferon gamma; MDSC, myeloid-derived suppressor cell; MITF, microphthalmia-associated transcription factor; TCCM, tumor cell-conditioned medium.

Article Snippet: After the injection, the mice were anesthetized with isoflurane (2% in 1 L/min oxygen), and bioluminescence images were acquired using the IVIS Lumina III XRMS (PerkinElmer, Waltham, Massachusetts, USA).

Techniques: Expressing, In Vivo, Isolation, FACS, Cell Culture, Injection, Staining, Flow Cytometry, Activity Assay, Derivative Assay